Form 4: Corcept Therapeutics Executive Exercises Options and Sells Shares

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, executed stock options and sold shares, according to a recent SEC filing.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options to acquire 14,037 shares of common stock at a price of $3.29 per share.
• He then sold 11,000 of these shares at a weighted average price of $50.5047 per share, with individual sale prices ranging from $50.39 to $50.84.
• Following these transactions, Robb directly owns 23,156 shares of common stock and indirectly owns 9,665 shares through a custodial account for his child.
• The sale of shares was conducted under a pre-arranged 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing insider trading activity, which is neither positive nor negative in itself. It reflects standard executive compensation practices.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Amgen (AMGN) or Gilead Sciences (GILD).
• The exercise of stock options and subsequent sale of shares is a typical form of executive compensation, similar to what is seen at companies like Regeneron (REGN) or Vertex Pharmaceuticals (VRTX).
• The reported prices are within the expected range for a company of this size and stage, and the sale price is significantly higher than the exercise price, indicating a profitable transaction for the executive.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the sale of shares, but this is likely to be minimal given the pre-arranged nature of the sale.
• The exercise of options and sale of shares is a standard part of executive compensation and is not expected to have a significant impact on other stakeholders.

Key Dates

Keywords

insider trading, stock options, SEC Form 4, Corcept Therapeutics, CORT, Gary Charles Robb, 10b5-1 plan, executive compensation